Clinical Trial Update: Bortezomib and High-dose Melphalan at Myeloma Relapse [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating bortezomib combined with high-dose melphalan for relapsed multiple myeloma. The current status of the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Melphalan (Melphalan)
• Velcade (bortezomib)

Snippet

Sponsor: Nordic Myeloma Study Group | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN